Breast Specific Gamma Imaging (BSGI)/ Molecular Breast Imaging (MBI)

2012 ◽  
Vol 03 (01) ◽  
pp. 97-100
Author(s):  
Samart Rajchadara
Keyword(s):  
Breast Imaging ◽  
Molecular Breast Imaging ◽  
Gamma Imaging

Results of a Multicenter Patient Registry to Determine the Clinical Impact of Breast-Specific Gamma Imaging, a Molecular Breast Imaging Technique

2012 ◽  
Vol 198 (1) ◽  
pp. W69-W75 ◽  
Author(s):  
Jean M. Weigert ◽  
Margaret L. Bertrand ◽  
Leora Lanzkowsky ◽  
Lillian H. Stern ◽  
Douglas A. Kieper
Keyword(s):  
Breast Imaging ◽  
Imaging Technique ◽  
Clinical Impact ◽  
Patient Registry ◽  
Molecular Breast Imaging ◽  
Gamma Imaging

scholarly journals Molecular breast imaging and background uptake of fibroglandular tissue as tools to predict neoplasms in dense breasts

Mastology ◽  
2021 ◽  
Vol 31 ◽  
Author(s):  
Carla Lima Santos Viviani ◽  
Lucimara Priscila Veras ◽  
Dionísio Nepomuceno Viviani ◽  
Amanda Sofia Silva Mascarenhas ◽  
Rivadávio Fernandes Batista de Amorim
Keyword(s):  
Cancer Detection ◽  
Breast Imaging ◽  
Low Cost ◽  
Screening Method ◽  
High Patient Satisfaction ◽  
Molecular Breast Imaging ◽  
Gamma Imaging ◽  
Complementary Method ◽  
Dense Breasts ◽  
Fibroglandular Tissue

The sensitivity of mammography as a screening method is low in dense breasts, which are associated with a high risk of developing tumors. Thus, molecular breast imaging (MBI) with background uptake (BPU) of fibroglandular tissue can be used as a complementary method. The aim of this review was to synthesize the existing evidence on these important diagnostic imaging tools. Three electronic databases were searched to identify original articles, including publications dating from September 2010 and September 2020, in English, conducted in any location, and addressing at least one aspect related to dense breasts and Breast-specific gamma-imaging (BSGI). In total, 22 studies were reviewed. Several advantages of MBI and BPU as complementary methods of screening for dense breasts were found. Among them, we can mention the increase in breast cancer detection rate, easy implementation in clinical practice, high patient satisfaction, low cost and good reproducibility. In view of the good results found in our review, we can conclude that the implementation of MBI, especially with BPU, can be a promising complementary tool for screening of dense breasts.

scholarly journals Molecular breast imaging detected invasive lobular carcinoma in dense breasts: A case report

2019 ◽  
Vol 7 (3) ◽  
pp. 442-444 ◽  
Author(s):  
Naziya Samreen ◽  
Katie N. Hunt ◽  
Carrie B. Hruska ◽  
Deborah J. Rhodes
Keyword(s):  
Case Report ◽  
Invasive Lobular Carcinoma ◽  
Breast Imaging ◽  
Lobular Carcinoma ◽  
Molecular Breast Imaging ◽  
Dense Breasts

Molecular Breast Imaging at Ultra-Low Radiation Dose

2020 ◽  
Vol 215 (2) ◽  
pp. W30-W30
Author(s):  
Matthew F. Covington ◽  
Matthew Brown
Keyword(s):  
Radiation Dose ◽  
Breast Imaging ◽  
Low Radiation Dose ◽  
Molecular Breast Imaging

Molecular Breast Imaging: A Scientific Review

2021 ◽  
Author(s):  
Katie N Hunt
Keyword(s):  
Breast Cancer ◽  
Breast Imaging ◽  
Breast Mri ◽  
Cancer Staging ◽  
Scientific Review ◽  
Molecular Breast Imaging ◽  
Breast Cancer Staging ◽  
Fast Learning ◽  
Technical Advances ◽  
History Of

Abstract Molecular breast imaging (MBI) is a nuclear medicine technique that has evolved considerably over the past two decades. Technical advances have allowed reductions in administered doses to the point that they are now acceptable for screening. The most common radiotracer used in MBI, 99mTc-sestamibi, has a long history of safe use. Biopsy capability has become available in recent years, with early clinical experience demonstrating technically successful biopsies of MBI-detected lesions. MBI has been shown to be an effective supplemental screening tool in women with dense breasts and is also utilized for breast cancer staging, assessment of response to neoadjuvant chemotherapy, problem solving, and as an alternative to breast MRI in women who have a contraindication to MRI. The degree of background parenchymal uptake on MBI shows promise as a tool for breast cancer risk stratification. Radiologist interpretation is guided by a validated MBI lexicon that mirrors the BI-RADS lexicon. With short interpretation times, a fast learning curve for radiologists, and a substantially lower cost than breast MRI, MBI provides many benefits in the practices in which it is utilized. This review will discuss the current state of MBI technology, clinical applications of MBI, MBI interpretation, radiation dose associated with MBI, and the future of MBI.

Sign in / Sign up

Export Citation Format

Share Document